The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation ...
The following slide deck was published by The Goldman Sachs Group, Inc. in conjunction with their 2026 Q1 earnings call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results